Verona Pharma plc
VRNA Real Time Price USDRecent trades of VRNA by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by VRNA's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Treatment Sep. 19, 2023
-
Patent Title: Salt of a pyrimido[6,1-a]isoquinolin-4-one compound Nov. 08, 2022
-
Patent Title: Liquid inhalation formulation comprising rpl554 Mar. 16, 2021
-
Patent Title: Treatment Dec. 15, 2020
-
Patent Title: Compound and process Jul. 14, 2020
-
Patent Title: Drug combination of pde3/pde4 inhibitor and muscarinic receptor antagonist Nov. 12, 2019
-
Patent Title: Salt of a pyrimido[6,1-a]isoquinolin-4-one compound Nov. 05, 2019
-
Patent Title: Liquid inhalation formulation comprising rpl554 May. 01, 2018
-
Patent Title: Drug combination Aug. 01, 2017
-
Patent Title: Drug combination of pde3/pde4 inhibitor and muscarinic receptor antagonist Jul. 11, 2017
-
Patent Title: Crystalline form of pyrimido[6,1-a] isoquinolin-4-one compound Jun. 23, 2015
-
Patent Title: Derivatives of pyrimido[6,1-a]isoquinolin-4-one Aug. 14, 2012
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of VRNA in WallStreetBets Daily Discussion
Recent insights relating to VRNA
Recent picks made for VRNA stock on CNBC
ETFs with the largest estimated holdings in VRNA
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view VRNA Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.